Triiodothyronine Treatment reverses Depression-Like Behavior in a triple-transgenic animal model of Alzheimer's Disease.
Alzheimer’s disease
Depression
Triiodothyronine
hippocampus
Journal
Metabolic brain disease
ISSN: 1573-7365
Titre abrégé: Metab Brain Dis
Pays: United States
ID NLM: 8610370
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
25
01
2022
accepted:
19
07
2022
pubmed:
12
8
2022
medline:
22
11
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Alzheimer disease's (AD) is a neurodegenerative disorder characterized by cognitive and behavioral impairment. The central nervous system is an important target of thyroid hormones (TH). An inverse association between serum triiodothyronine (T3) levels and the risk of AD symptoms and progression has been reported. We investigated the effects of T3 treatment on the depression-like behavior in male transgenic 3xTg-AD mice. Animals were divided into 2 groups treated with daily intraperitoneal injections of 20 ng/g of body weight (b.w.) L-T3 (T3 group) or saline (vehicle, control group). The experimental protocol lasted 21 days, and behavioral tests were conducted on days 18-20. At the end of the experiment, the TH profile and hippocampal gene expression were evaluated. The T3-treated group significantly increased serum T3 and decreased thyroxine (T4) levels. When compared to control hippocampal samples, the T3 group exhibited attenuated glycogen synthase kinase-3 (GSK3), metalloproteinase 10 (ADAM10), amyloid-beta precursor-protein (APP), serotonin transporter (SERT), 5HT1A receptor, monocarboxylate transporter 8 (MCT8) and bone morphogenetic protein 7 (BMP-7) gene expression, whereas augmented superoxide dismutase 2 (SOD2) and Hairless gene expression. T3-treated animals also displayed reduced immobility time in both the tail suspension and forced swim tests, and in the latter presented a higher latency time compared to the control group. Therefore, our findings suggest that in an AD mouse model, T3 supplementation promotes improvements in depression-like behavior, through the modulation of the serotonergic related genes involved in the transmission mediated by 5HT1A receptors and serotonin reuptake, and attenuated disease progression.
Identifiants
pubmed: 35951206
doi: 10.1007/s11011-022-01055-9
pii: 10.1007/s11011-022-01055-9
doi:
Substances chimiques
Triiodothyronine
06LU7C9H1V
Glycogen Synthase Kinase 3
EC 2.7.11.26
Thyroid Hormones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2735-2750Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Accorroni A, Giorgi FS, Donzelli R et al (2017) Thyroid hormone levels in the cerebrospinal fluid correlate with disease severity in euthyroid patients with Alzheimer’s disease. Endocrine 55:981–984. https://doi.org/10.1007/s12020-016-0897-6
doi: 10.1007/s12020-016-0897-6
pubmed: 26902870
Ahmed OM, El-Gareib AW, El-bakry AM et al (2008) Thyroid hormones states and brain development interactions. Int J Dev Neurosci 26:147–209. https://doi.org/10.1016/j.ijdevneu.2007.09.011
doi: 10.1016/j.ijdevneu.2007.09.011
pubmed: 18031969
Alois, Gessl, Rosa Lemmens-Gruber and AK-W (2012) Thyroid Disorders. Handb Exp Pharmacol 214:361–386. https://doi.org/10.1007/978-3-642-30726-3
doi: 10.1007/978-3-642-30726-3
Barnes NM, Sharp T (1999) 5-HTR_review_Neurophar.pdf. Neuropharmacology 38:1083–1152
doi: 10.1016/S0028-3908(99)00010-6
pubmed: 10462127
Bauer M, Goetz T, Glenn T, Whybrow PC (2008) The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol 20:1101–1114. https://doi.org/10.1111/j.1365-2826.2008.01774.x
doi: 10.1111/j.1365-2826.2008.01774.x
pubmed: 18673409
Bauer M, Heinz A, Whybrow PC (2002) Thyroid hormones, serotonin and mood: Of synergy and significance in the adult brain. Mol Psychiatry 7:140–156. https://doi.org/10.1038/sj.mp.4000963
doi: 10.1038/sj.mp.4000963
pubmed: 11840307
Bavarsad K, Hosseini M, Hadjzadeh MAR, Sahebkar A (2019) The effects of thyroid hormones on memory impairment and Alzheimer’s disease. J Cell Physiol 234:14633–14640. https://doi.org/10.1002/jcp.28198
doi: 10.1002/jcp.28198
Beaulieu JM, Sotnikova TD, Marion S et al (2005) An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261–273. https://doi.org/10.1016/j.cell.2005.05.012
doi: 10.1016/j.cell.2005.05.012
pubmed: 16051150
Beurel E, Grieco SF, Jope RS (2015) Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases. Pharmacol Ther 148:114–131. https://doi.org/10.1016/j.pharmthera.2014.11.016
doi: 10.1016/j.pharmthera.2014.11.016
pubmed: 25435019
Bianco AC, Anderson G, Forrest D et al (2014) American thyroid association guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid 24:88–168. https://doi.org/10.1089/thy.2013.0109
doi: 10.1089/thy.2013.0109
pubmed: 24001133
pmcid: 3887458
Boccardi V, Westman E, Pelini L et al (2019) Differential associations of IL-4 with hippocampal subfields in mild cognitive impairment and Alzheimer’s disease. Front Aging Neurosci 11. https://doi.org/10.3389/fnagi.2018.00439
Burns A (1990) Disorders of affect in alzheimer’s disease. Int J Geriatr Psychiatry 5:63–66. https://doi.org/10.1002/gps.930050202
doi: 10.1002/gps.930050202
Can A, Dao DT, Terrillion CE et al (2011) The tail suspension test. J Vis Exp 2–7. https://doi.org/10.3791/3769
Chaalal A, Poirier R, Blum D et al (2019) Thyroid Hormone Supplementation Restores Spatial Memory, Hippocampal Markers of Neuroinflammation, Plasticity-Related Signaling Molecules, and β-Amyloid Peptide Load in Hypothyroid Rats. Mol Neurobiol 56:722–735. https://doi.org/10.1007/s12035-018-1111-z
doi: 10.1007/s12035-018-1111-z
pubmed: 29796989
Chaker L, Wolters FJ, Bos D et al (2016) Thyroid function and the risk of dementia: The Rotterdam Study. Neurology 87:1688–1695. https://doi.org/10.1212/WNL.0000000000003227
doi: 10.1212/WNL.0000000000003227
pubmed: 27638924
Choi HJ, Byun MS, Yi D et al (2017) Associations of thyroid hormone serum levels with in-vivo Alzheimer’s disease pathologies. Alzheimer’s Res Ther 9:1–9. https://doi.org/10.1186/s13195-017-0291-5
doi: 10.1186/s13195-017-0291-5
Cochet M, Donneger R, Cassier E et al (2013) 5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem Neurosci 4:130–140. https://doi.org/10.1021/cn300095t
doi: 10.1021/cn300095t
pubmed: 23336052
Colciaghi F, Marcello E, Borroni B et al (2004) Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62:498–501. https://doi.org/10.1212/01.WNL.0000106953.49802.9C
doi: 10.1212/01.WNL.0000106953.49802.9C
pubmed: 14872043
Cooper-Kazaz R, Lerer B (2008) Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 11:685–699. https://doi.org/10.1017/S1461145707008206
doi: 10.1017/S1461145707008206
pubmed: 18047754
Cortés N, Andrade V, Maccioni RB (2018) Behavioral and Neuropsychiatric Disorders in Alzheimer’s Disease. J Alzheimer’s Dis 63:899–910. https://doi.org/10.3233/JAD-180005
doi: 10.3233/JAD-180005
Cummings JL (2000) Cognitive and behavioral heterogeneity in Alzheimer’s disease: Seeking the neurobiological basis. Neurobiol Aging 21:845–861. https://doi.org/10.1016/S0197-4580(00)00183-4
doi: 10.1016/S0197-4580(00)00183-4
pubmed: 11124429
de Flores R, La Joie R, Chételat G (2015a) Structural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease. Neuroscience 309:29–50. https://doi.org/10.1016/j.neuroscience.2015.08.033
doi: 10.1016/j.neuroscience.2015.08.033
pubmed: 26306871
de Flores R, La Joie R, Landeau B et al (2015b) Effects of age and Alzheimer’s disease on hippocampal subfields: Comparison between manual and freesurfer volumetry. Hum Brain Mapp 36:463–474. https://doi.org/10.1002/hbm.22640
doi: 10.1002/hbm.22640
pubmed: 25231681
Denereaz N, Medicine I (2014) Severe But Not Mild Alterations. 136
Desouza LA, Ladiwala U, Daniel SM et al (2005) Thyroid hormone regulates hippocampal neurogenesis in the adult rat brain. Mol Cell Neurosci 29:414–426. https://doi.org/10.1016/j.mcn.2005.03.010
doi: 10.1016/j.mcn.2005.03.010
pubmed: 15950154
Duda P, Wiśniewski J, Wójtowicz T et al (2018) Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. Expert Opin Ther Targets 22:833–848. https://doi.org/10.1080/14728222.2018.1526925
doi: 10.1080/14728222.2018.1526925
pubmed: 30244615
Farbood Y, Shabani S, Sarkaki A et al (2017) Peripheral and central administration of T3 improved the histological changes, memory and the dentate gyrus electrophysiological activity in an animal model of Alzheimer’s disease. Metab Brain Dis 32:693–701. https://doi.org/10.1007/s11011-016-9947-2
doi: 10.1007/s11011-016-9947-2
pubmed: 28124751
Fernandez SP, Muzerelle A, Scotto-Lomassese S et al (2017) Constitutive and Acquired Serotonin Deficiency Alters Memory and Hippocampal Synaptic Plasticity. Neuropsychopharmacology 42:512–523. https://doi.org/10.1038/npp.2016.134
doi: 10.1038/npp.2016.134
pubmed: 27461084
Filali M, Lalonde R, Theriault P et al (2012) Cognitive and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer’s disease expressing mutated APP, PS1, and Mapt (3xTg-AD). Behav Brain Res 234:334–342. https://doi.org/10.1016/j.bbr.2012.07.004
doi: 10.1016/j.bbr.2012.07.004
pubmed: 22796601
Frisoni GB, Ganzola R, Canu E et al (2008) Mapping local hippocampal changes in Alzheimer’s disease and normal ageing with MRI at 3 Tesla. Brain 131:3266–3276. https://doi.org/10.1093/brain/awn280
doi: 10.1093/brain/awn280
pubmed: 18988639
Fu AL, Zhou CY, Chen X (2010) Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer’s disease. Neuropharmacology 58:722–729. https://doi.org/10.1016/j.neuropharm.2009.12.020
doi: 10.1016/j.neuropharm.2009.12.020
pubmed: 20045708
Fuhrer TE, Palpagama TH, Waldvogel HJ et al (2017) Impaired expression of GABA transporters in the human Alzheimer’s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus. Neuroscience 351:108–118. https://doi.org/10.1016/j.neuroscience.2017.03.041
doi: 10.1016/j.neuroscience.2017.03.041
pubmed: 28385633
Ge JF, Peng YY, Qi CC et al (2014) Depression-like behavior in subclinical hypothyroidism rat induced by hemi-thyroid electrocauterization. Endocrine 45:430–438. https://doi.org/10.1007/s12020-013-0001-4
doi: 10.1007/s12020-013-0001-4
pubmed: 23794115
Glikmann-Johnston Y, Saling MM, Reutens DC, Stout JC (2015) Hippocampal 5-HT1A receptor and spatial learning and memory. Front Pharmacol 6:1–10. https://doi.org/10.3389/fphar.2015.00289
doi: 10.3389/fphar.2015.00289
Griebel G, Stemmelin J, Lopez-Grancha M et al (2019) The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents. Sci Rep 9:1–15. https://doi.org/10.1038/s41598-019-54557-5
doi: 10.1038/s41598-019-54557-5
Grieve SM, Clark CR, Williams LM et al (2005) Preservation of limbic and paralimbic structures in aging. Hum Brain Mapp 25:391–401. https://doi.org/10.1002/hbm.20115
doi: 10.1002/hbm.20115
pubmed: 15852381
pmcid: 6871717
Hamidi S, Aliesky H, Chen CR et al (2010) Variable suppression of serum thyroxine in female mice of different inbred Strains by triiodothyronine Administered in drinking water. Thyroid 20:1157–1162. https://doi.org/10.1089/thy.2010.0117
doi: 10.1089/thy.2010.0117
pubmed: 20860425
pmcid: 2947419
Hardy J, Cowburn R, Barton A et al (1987a) Region-specific loss of glutamate innervation in Alzheimer’s disease. Neurosci Lett 73:77–80. https://doi.org/10.1016/0304-3940(87)90034-6
doi: 10.1016/0304-3940(87)90034-6
pubmed: 2882446
Hardy J, Cowburn R, Barton A et al (1987b) A disorder of cortical GABAergic innervation in Alzheimer’s disease. Neurosci Lett 73:192–196. https://doi.org/10.1016/0304-3940(87)90016-4
doi: 10.1016/0304-3940(87)90016-4
pubmed: 3822251
Huang M, Liang Y, Chen H et al (2018) The Role of fluoxetine in activating Wnt/β-catenin signaling and repressing β-amyloid production in an Alzheimer mouse model. Front Aging Neurosci 10:1–13. https://doi.org/10.3389/fnagi.2018.00164
doi: 10.3389/fnagi.2018.00164
pubmed: 29403371
pmcid: 5780404
Iacono D, Volkman I, Nennesmo I et al (2014) Neuropathologic assessment of dementia markers in identical and fraternal twins. Brain Pathol 24:317–333. https://doi.org/10.1111/bpa.12127
doi: 10.1111/bpa.12127
pubmed: 24450926
pmcid: 4065212
Izaguirre MF, Casco VH (2016) E-cadherin roles in animal biology: A perspective on thyroid hormone-influence. Cell Commun Signal 14:1–16. https://doi.org/10.1186/s12964-016-0150-1
doi: 10.1186/s12964-016-0150-1
Kalpouzos G, Chételat G, Baron JC et al (2009) Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging 30:112–124. https://doi.org/10.1016/j.neurobiolaging.2007.05.019
doi: 10.1016/j.neurobiolaging.2007.05.019
pubmed: 17630048
Karch CM, Goate AM (2015) Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry 77:43–51. https://doi.org/10.1016/j.biopsych.2014.05.006
doi: 10.1016/j.biopsych.2014.05.006
pubmed: 24951455
Kelly TF, Lieberman DZ (2009) Long term augmentation with T3 in refractory major depression. J Affect Disord 115:230–233. https://doi.org/10.1016/j.jad.2008.09.022
doi: 10.1016/j.jad.2008.09.022
pubmed: 19108898
Kim M, Suh J, Romano D et al (2009) Potential late-onset Alzheimer’s disease-associated mutations in the ADAM10 gene attenuate α-secretase activity. Hum Mol Genet 18:3987–3996. https://doi.org/10.1093/hmg/ddp323
doi: 10.1093/hmg/ddp323
pubmed: 19608551
pmcid: 2748890
Kuruva CS, Reddy PH (2017) Amyloid beta modulators and neuroprotection in Alzheimer’s disease: a critical appraisal. Drug Discov Today 22:223–233. https://doi.org/10.1016/j.drudis.2016.10.010
doi: 10.1016/j.drudis.2016.10.010
pubmed: 27794478
La Joie R, Fouquet M, Mézenge F et al (2010) Differential effect of age on hippocampal subfields assessed using a new high-resolution 3T MR sequence. NeuroImage 53:506–514. https://doi.org/10.1016/j.neuroimage.2010.06.024
doi: 10.1016/j.neuroimage.2010.06.024
pubmed: 20600996
Lambert JC, Araria-Goumidi L, Myllykangas L et al (2002) Contribution of APOE promoter polymorphisms to Alzheimer’s disease risk. Neurology 59:59–66. https://doi.org/10.1212/WNL.59.1.59
doi: 10.1212/WNL.59.1.59
pubmed: 12105308
Lanfumey L, Hamon M (2000) Central 5-HT(1A) receptors: Regional distribution and functional characteristics. Nucl Med Biol 27:429–435. https://doi.org/10.1016/S0969-8051(00)00107-4
doi: 10.1016/S0969-8051(00)00107-4
pubmed: 10962246
Lee JH, Lee M, Park JA et al (2018) Effects of hypothyroidism on serotonin 1A receptors in the rat brain. Psychopharmacology 235:729–736. https://doi.org/10.1007/s00213-017-4799-y
doi: 10.1007/s00213-017-4799-y
pubmed: 29209734
Letra L, Santana I, Seiça R (2014) Obesity as a risk factor for Alzheimer’s disease: the role of adipocytokines. Metab Brain Dis 29:563–568. https://doi.org/10.1007/s11011-014-9501-z
doi: 10.1007/s11011-014-9501-z
pubmed: 24553879
Li X, Zhu W, Roh MS et al (2004) In vivo regulation of glycogen synthase kinase-3β (GSK3β) by serotonergic activity in mouse brain. Neuropsychopharmacology 29:1426–1431. https://doi.org/10.1038/sj.npp.1300439
doi: 10.1038/sj.npp.1300439
pubmed: 15039769
Lifschytz T, Segman R, Shalom G et al (2006) Basic Mechanisms of Augmentation of Antidepressant Effects with Thyroid Hormone. Curr Drug Targets 7:203–210. https://doi.org/10.2174/138945006775515482
doi: 10.2174/138945006775515482
pubmed: 16475961
Lifschytz T, Zozulinsky P, Eitan R et al (2011) Effect of triiodothyronine on antidepressant screening tests in mice and on presynaptic 5-HT 1A receptors: Mediation by thyroid hormone α receptors. J Pharmacol Exp Ther 337:494–502. https://doi.org/10.1124/jpet.111.179564
doi: 10.1124/jpet.111.179564
pubmed: 21317357
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-∆∆CT method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262
doi: 10.1006/meth.2001.1262
pubmed: 11846609
Maixner DW, Weng H-R (2013) The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. J Pharm Pharmacol 1:001. https://doi.org/10.13188/2327-204X.1000001
doi: 10.13188/2327-204X.1000001
Malinverno M, Carta M, Epis R et al (2010) Synaptic localization and activity of ADAM10 regulate excitatory synapses through N-cadherin cleavage. J Neurosci 30:16343–16355. https://doi.org/10.1523/JNEUROSCI.1984-10.2010
doi: 10.1523/JNEUROSCI.1984-10.2010
pubmed: 21123580
pmcid: 6634827
Manuel Gomez Saez J (2012) Possible Usefulness of Growth Hormone/Insulin-like Growth Factor-I Axis in Alzheimer’s Disease Treatment. Endocrine, Metab Immune Disord Targets 12:274–286. https://doi.org/10.2174/187153012802002857
Manzano J, Bernal J, Morte B (2007) Influence of thyroid hormones on maturation of rat cerebellar astrocytes. Int J Dev Neurosci 25:171–179. https://doi.org/10.1016/j.ijdevneu.2007.01.003
doi: 10.1016/j.ijdevneu.2007.01.003
pubmed: 17408906
Marcello E, Borroni B, Pelucchi S et al (2017) ADAM10 as a therapeutic target for brain diseases: From developmental disorders to Alzheimer’s disease. Expert Opin Ther Targets 21:1017–1026. https://doi.org/10.1080/14728222.2017.1386176
doi: 10.1080/14728222.2017.1386176
pubmed: 28960088
Massaad CA, Washington TM, Pautler RG, Klann E (2009) Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 106:13576–13581. https://doi.org/10.1073/pnas.0902714106
doi: 10.1073/pnas.0902714106
pubmed: 19666610
pmcid: 2726352
Masters MC, Morris JC, Roe CM (2015) “Noncognitive” symptoms of early Alzheimer disease. Neurology 84 617 LP – 622. https://doi.org/10.1212/WNL.0000000000001238
Mendes-de-Aguiar CBN, Alchini R, Decker H et al (2008) Thyroid hormone increases astrocytic glutamate uptake and protects astrocytes and neurons against glutamate toxicity. J Neurosci Res 86:3117–3125. https://doi.org/10.1002/jnr.21755
doi: 10.1002/jnr.21755
pubmed: 18543341
Mody I, Pearce RA (2004) Diversity of inhibitory neurotransmission through GABA A receptors. Trends Neurosci 27:569–575. https://doi.org/10.1016/j.tins.2004.07.002
doi: 10.1016/j.tins.2004.07.002
pubmed: 15331240
Moog NK, Entringer S, Heim C et al (2017) Influence of maternal thyroid hormones during gestation on fetal brain development. Neuroscience 342:68–100. https://doi.org/10.1016/j.neuroscience.2015.09.070
doi: 10.1016/j.neuroscience.2015.09.070
pubmed: 26434624
Murakami K, Murata N, Noda Y et al (2011) SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 286:44557–44568. https://doi.org/10.1074/jbc.M111.279208
doi: 10.1074/jbc.M111.279208
pubmed: 22072713
pmcid: 3247976
Newman ME, Agid O, Gur E, Lerer B (2000) Pharmacological mechanisms of T3 augmentation of antidepressant action. Int J Neuropsychopharmacol 3:187–191. https://doi.org/10.1017/S1461145700001875
doi: 10.1017/S1461145700001875
pubmed: 11343595
Noristani HN, Verkhratsky A, Rodríguez JJ (2012) High tryptophan diet reduces CA1 intraneuronal β-amyloid in the triple transgenic mouse model of Alzheimer’s disease. Aging Cell 11:810–822. https://doi.org/10.1111/j.1474-9726.2012.00845.x
doi: 10.1111/j.1474-9726.2012.00845.x
pubmed: 22702392
O’Barr SA, Oh JS, Ma C et al (2006) Thyroid hormone regulates endogenous amyloid-β precursor protein gene expression and processing in both in vitro and in vivo models. Thyroid 16:1207–1213. https://doi.org/10.1089/thy.2006.16.1207
doi: 10.1089/thy.2006.16.1207
pubmed: 17199430
Oddo S, Caccamo A, Shepherd JD et al (2003) Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles. Intracellular A and Synaptic Dysfunction
Oliveira KC, da Conceição RR, Piedade GC et al (2015) Thyroid hormone modulates neuroglobin and cytoglobin in rat brain. Metab Brain Dis 30:1401–1408. https://doi.org/10.1007/s11011-015-9718-5
doi: 10.1007/s11011-015-9718-5
pubmed: 26334191
Owens DF, Kriegstein AR (2002) Is there more to GABA than synaptic inhibition? Nat Rev Neurosci 3:715–727. https://doi.org/10.1038/nrn919
doi: 10.1038/nrn919
pubmed: 12209120
Perez Ortiz JM, Swerdlow RH (2019) Mitochondrial dysfunction in Alzheimer’s disease: Role in pathogenesis and novel therapeutic opportunities. Br J Pharmacol 176:3489–3507. https://doi.org/10.1111/bph.14585
doi: 10.1111/bph.14585
pubmed: 30675901
pmcid: 6715612
Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. 266:730–732
Porsolt RD, Bertin A, Blavet N et al (1979) Immobility induced by forced swimming in rats: Effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 57:201–210. https://doi.org/10.1016/0014-2999(79)90366-2
doi: 10.1016/0014-2999(79)90366-2
pubmed: 488159
Procaccini C, Santopaolo M, Faicchia D et al (2016) Role of metabolism in neurodegenerative disorders. Metabolism 65:1376–1390. https://doi.org/10.1016/j.metabol.2016.05.018
doi: 10.1016/j.metabol.2016.05.018
pubmed: 27506744
Quentin E, Belmer A, Maroteaux L (2018) Somato-Dendritic Regulation of Raphe Serotonin Neurons; A Key to Antidepressant Action. Front Neurosci 12:1–11. https://doi.org/10.3389/fnins.2018.00982
doi: 10.3389/fnins.2018.00982
Quinlan P, Horvath A, Wallin A, Svensson J (2019) Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of Alzheimer’s disease. Psychoneuroendocrinology 99:112–119. https://doi.org/10.1016/j.psyneuen.2018.09.002
doi: 10.1016/j.psyneuen.2018.09.002
pubmed: 30223192
Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7:137–152. https://doi.org/10.1038/nrneurol.2011.2
doi: 10.1038/nrneurol.2011.2
pubmed: 21304480
pmcid: 3339565
Roberts E, Kuriyama K (1968) Biochemical-physiology correlations in studies of the γ-aminobutyric acid system. Brain Res 8:1–35. https://doi.org/10.1016/0006-8993(68)90170-4
doi: 10.1016/0006-8993(68)90170-4
pubmed: 4870412
Roth KA, Katz RJ (1979) Stress, behavioral arousal, and open field activity-A reexamination of emotionality in the rat. Neurosci Biobehav Rev 3:247–263. https://doi.org/10.1016/0149-7634(79)90012-5
doi: 10.1016/0149-7634(79)90012-5
pubmed: 542239
Sathya M, Premkumar P, Karthick C et al (2012) BACE1 in Alzheimer’s disease. Clin Chim Acta 414:171–178. https://doi.org/10.1016/j.cca.2012.08.013
doi: 10.1016/j.cca.2012.08.013
pubmed: 22926063
Serenó L, Coma M, Rodríguez M et al (2009) A novel GSK-3β inhibitor reduces Alzheimer’s pathology and rescues neuronal loss in vivo. Neurobiol Dis 35:359–367. https://doi.org/10.1016/j.nbd.2009.05.025
doi: 10.1016/j.nbd.2009.05.025
pubmed: 19523516
Steinberg M, Tschanz JAT, Corcoran C et al (2004) The persistence of neuropsychiatric symptoms in dementia: The Cache County Study. Int J Geriatr Psychiatry 19:19–26. https://doi.org/10.1002/gps.1025
doi: 10.1002/gps.1025
pubmed: 14716695
Stelzmann RA, Norman Schnitzlein H, Reed Murtagh F (1995) An english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”. Clin Anat 8:429–431. https://doi.org/10.1002/ca.980080612
doi: 10.1002/ca.980080612
pubmed: 8713166
Sterniczuk R, Antle MC, Laferla FM, Dyck RH (2010) Characterization of the 3xTg-AD mouse model of Alzheimer’s disease: Part 2. Behavioral and cognitive changes. Brain Res 1348:149–155. https://doi.org/10.1016/j.brainres.2010.06.011
doi: 10.1016/j.brainres.2010.06.011
pubmed: 20558146
Stohn JP, Martinez ME, Hernandez A (2016) Decreased anxiety- and depression-like behaviors and hyperactivity in a type 3 deiodinase-deficient mouse showing brain thyrotoxicosis and peripheral hypothyroidism. Psychoneuroendocrinology 74:46–56. https://doi.org/10.1016/j.psyneuen.2016.08.021
doi: 10.1016/j.psyneuen.2016.08.021
pubmed: 27580013
pmcid: 5159228
Teri L, Truax P, Logsdon R et al (1992) Assessment of behavioral problems in dementia: the revised memory and behavior problems checklist. Psychol Aging 7:622–631. https://doi.org/10.1037/0882-7974.7.4.622
doi: 10.1037/0882-7974.7.4.622
pubmed: 1466831
Thathiah A, De Strooper B (2011) The role of G protein-coupled receptors in the pathology of Alzheimer’s disease. Nat Rev Neurosci 12:73–87. https://doi.org/10.1038/nrn2977
doi: 10.1038/nrn2977
pubmed: 21248787
Thierry B, Simon P, Porsolt RD (1986) Psychopharmacology The tail suspension test: Ethical considerations. Psychopharmacology 90:284–285
doi: 10.1007/BF00181261
pubmed: 3097714
Touma KTB, Zoucha AM, Scarff JR (2017) Liothyronine for depression: A review and guidance for safety monitoring. Innov Clin Neurosci 14:24–29
pubmed: 28584694
pmcid: 5451035
Van Rensburg SJ, Van Zyl JM, Potocnik FCV et al (2006) The effect of stress on the antioxidative potential of serum: Implications for Alzheimer’s disease. Metab Brain Dis 21:171–179. https://doi.org/10.1007/s11011-006-9020-7
doi: 10.1007/s11011-006-9020-7
pubmed: 16770696
Webster SJ, Bachstetter AD, Nelson PT et al (2014) Using mice to model Alzheimer’s dementia: An overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 5:1–23. https://doi.org/10.3389/fgene.2014.00088
doi: 10.3389/fgene.2014.00088
Xia D, Watanabe H, Wu B et al (2015) Presenilin-1 knockin mice reveal loss-of-function mechanism for familial alzheimer’s disease. Neuron 85:967–981. https://doi.org/10.1016/j.neuron.2015.02.010
doi: 10.1016/j.neuron.2015.02.010
pubmed: 25741723
pmcid: 4358812
Zhang Z 1, Bisschop1 PH, Foppen E 1, van Beeren HC 1, Kalsbeek A 1, 2, A. Boelen1 EF 3 (2006) A model for chronic, intrahypothalamic thyroid hormone administration in the rat. Biomed Res 02155:1–28. https://doi.org/10.1165/rcmb.2011-0385OC
Zendedel A, Kashani IR, Azimzadeh M et al (2016) Regulatory effect of triiodothyronine on brain myelination and astrogliosis after cuprizone-induced demyelination in mice. Metab Brain Dis 31:425–433. https://doi.org/10.1007/s11011-015-9781-y
doi: 10.1007/s11011-015-9781-y
pubmed: 26725831
Zhao Y, Zhao B (2013) Review Article Oxidative Stress and the Pathogenesis of Alzheimer ’ s Disease. Oxid Med Cell Longev 2013:. https://doi.org/10.1155
Zheng P, Tong W (2017) IGF-1: an endogenous link between traumatic brain injury and Alzheimer disease? J Neurosurg Sci 61:416–421
doi: 10.23736/S0390-5616.16.03431-7
pubmed: 26349470
Zheng P, Tong W (2017) IGF-1: an endogenous link between traumatic brain injury and Alzheimer disease? J Neurosurg Sci 61:416–421